Table 1.

Characterization of TNBC patient–derived tumor xenografts

Sample IDSourcePTEN IHC (H-score)PIK3CA status (MassArray)BRCA status (Sanger)PAM50

NOTE: Expression of PTEN and PIK3CA or BRCA1/2 mutational statuses of 3 tumor grafts derived from either primary or metastatic lesions of different patients with TNBCs. A minimum of 3 independent samples were used for PTEN quantification by immunohistochemistry. Molecular subtype analysis was conducted using PAM50 molecular analysis of Affymetrix microarrays.

Abbreviation: IHC, immunohistochemistry.

  • ↵aLow estrogen receptor expression by IHC.